FDA 503A Update: What the July 2026 PCAC Peptide Decision Means for Compounders and Physicians

The Headline

On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) met to review seven peptides nominated for inclusion on the 503A Bulks List — the list that lets licensed pharmacists and physicians compound with a bulk drug substance that has no USP monograph and is not a component of an FDA-approved drug.

For all seven, FDA's briefing documents propose the same answer: do not add them to the list. The proposals cover both the free base and acetate salt forms of each substance, for a total of fourteen substances:

• BPC-157 (free base and acetate)
• KPV (free base and acetate)
• TB-500 (free base and acetate)
• MOTS-c (free base and acetate)
• Emideltide (free base and acetate)
• Epitalon (free base and acetate)
• Semax (free base and acetate)

This is one of the most consequential compounding-policy developments the peptide field has seen. Below is what the decision actually is, why FDA reached it, and — importantly — what it does and does not change today.

First, What the 503A Bulks List Actually Is

Section 503A of the Federal Food, Drug, and Cosmetic Act lets a compounded drug be exempt from certain approval, labeling, and CGMP requirements if it's compounded from a bulk drug substance that meets one of three conditions:

1. It complies with an applicable USP or NF monograph, or
2. It is a component of an FDA-approved drug, or
3. It appears on the 503A Bulks List developed by FDA.

None of these seven peptides has a USP monograph, and none is a component of an approved drug. That leaves door number three — the 503A Bulks List — as the only lawful path for a 503A pharmacy to compound them. That is exactly the door FDA is now proposing to keep closed for these substances.

The Four Criteria FDA Balanced

Under a 2019 final rule (84 FR 4696), FDA evaluates each nominated substance against four criteria and applies a balancing test — weighing each factor against the others on a substance-by-substance basis:

1. Physical and chemical characterization — is the substance well-defined and controllable?
2. Safety — what risks does using it in a compounded product raise?
3. Effectiveness — is there evidence it works (or doesn't) for the proposed use?
4. Historical use — has it been used in compounding, and for what conditions?

The Common Threads Across All Seven

Reading the seven briefing packages side by side, the same concerns recur:

• Not well-characterized. For every peptide, FDA flagged inconsistent naming conventions that don't follow established nomenclature standards (USAN, INN, IUPAC) and missing substance-specific quality data — impurity profiles, aggregate content, bacterial endotoxin, and microbial bioburden testing were frequently absent from the public literature.
• Little or no human effectiveness data for the proposed route. Most nominations proposed subcutaneous or injectable use, yet FDA repeatedly found no adequate clinical studies for that route and indication.
• Insufficient human safety data. For every substance, FDA cited a lack of clinical safety information and, for the injectable peptides, specific concern about immunogenicity driven by potential aggregation and peptide-related impurities.
• FDA-approved alternatives already exist for many of the nominated uses (wounds, inflammatory disease, insomnia), which weighs against adding an uncharacterized bulk substance.

Notably, the underlying nominations — filed by LDT Health Solutions (on behalf of the International Peptide Society) and Wells Pharmacy Network — were withdrawn by the nominators. FDA elected to proceed with the PCAC presentations anyway.

What This Does — and Does Not — Change Today

This is the part clinicians most need to hear correctly:

• These are proposals for the advisory committee, not final agency determinations. FDA states plainly that it will not issue a final determination until the advisory-committee input is considered and all reviews are finalized.
• A PCAC recommendation is advisory. FDA is not bound by it.
• Nothing about the FDA-approval status of these peptides changed: none was FDA-approved before, and none is now.

What the decision signals is a clear regulatory direction: FDA does not currently see the characterization, effectiveness, or safety evidence it would need to bless these substances for 503A compounding. Physicians and pharmacies should plan on continued — and likely tightening — access constraints for all seven.

Where to Go From Here

If your practice relies on any of these peptides, three moves are worth making now: (1) confirm the current sourcing pathway with your 503A compounding partner; (2) review whether an FDA-approved therapy fits the indication; and (3) follow the FDA/503A category updates as final determinations are issued.

Cluster deep-dives on each substance:

• BPC-157 — the ulcerative-colitis and tissue-repair nomination
• KPV — the α-MSH fragment nominated for wound healing and inflammation
• TB-500 — the thymosin β-4 fragment nominated for wound healing
• MOTS-c — the mitochondrial-derived peptide nominated for metabolic use
• Emideltide — the delta sleep-inducing peptide nominated for insomnia and withdrawal
• Epitalon — the pineal tetrapeptide nominated for insomnia
• Semax — the ACTH-fragment neuropeptide nominated for analgesia and cognition

Key Takeaways for Physicians

• FDA is proposing that none of the seven peptides (14 substances counting salt forms) be added to the 503A Bulks List.
• The recurring rationale is poor characterization, thin human effectiveness data for the proposed route, and insufficient safety data — plus immunogenicity concerns for injectables.
• These are advisory-committee proposals, not final rules; final determinations come later.
• With no USP monograph and no approved-drug pathway, the 503A Bulks List was the only compounding route — so the direction of travel points toward tighter access.
• Work with a 503A compounding partner and monitor final determinations before making sourcing decisions.

Frequently Asked Questions

Did the FDA ban BPC-157 and these other peptides?
Not exactly. FDA is proposing that they not be added to the 503A Bulks List, which is the list that authorizes compounding of bulk substances without a USP monograph or approved-drug status. These are advisory-committee proposals, not final determinations, and no final rule had been issued as of the briefing documents.

Which peptides were reviewed at the July 2026 PCAC meeting?
BPC-157, KPV, TB-500, and MOTS-c were discussed July 23; Emideltide, Epitalon, and Semax were discussed July 24 — each in both free base and acetate salt forms.

Why is FDA proposing not to list them?
Across all seven, FDA cited that the substances are not well-characterized, that there is little or no human evidence of effectiveness for the proposed (mostly injectable) routes, and that there is insufficient human safety data — including unassessed immunogenicity risk.

Are these peptides FDA-approved?
No. None of the seven is FDA-approved for any indication. That status has not changed as a result of the PCAC review.

What should physicians do now?
Confirm current access with a licensed 503A compounding partner, evaluate FDA-approved alternatives where they exist, and track the 503A regulatory updates for final determinations.

Track Live FDA Peptide Status

Regulatory status changes as PCAC hearings and FDA determinations roll out. Bookmark our FDA Peptide Status Tracker 2026 for the latest category and PCAC updates on every peptide.